Effect of Intravenous Dipyridamole on Cerebral Blood Flow in Humans
A PET Study

Hiroshi Ito, MD, PhD; Toshibumi Kinoshita, MD, PhD; Yoshikazu Tamura, MD, PhD; Ikuo Yokoyama, MD, PhD; Hidehiro Iida, DSc, PhD

Background and Purpose—Dipyridamole increases the concentration of circulating adenosine, which is a potent vasodilator, by inhibition of uptake of adenosine into the erythrocytes, and hence produces coronary vasodilation. However, the effects of dipyridamole on cerebral circulation is not pronounced. This study investigates the effects of intravenous dipyridamole on cerebral blood flow (CBF) in humans with use of positron emission tomography (PET).

Methods—In each of 13 healthy subjects, CBF was measured using 15O-labeled water and PET at rest and during hypercapnia, hypocapnia, and dipyridamole stress; corresponding CBF values were then compared.

Results—CBF values during dipyridamole stress were significantly lower than those measured at rest. The dipyridamole stress PaCO₂ was also significantly lower than the resting PaCO₂. The change in CBF during dipyridamole stress relative to PaCO₂ closely followed the relationship between CBF and PaCO₂ during hypocapnia.

Conclusions—These results indicate that the observed decrease in CBF during dipyridamole stress was caused by a decrease in PaCO₂ rather than by any direct action of dipyridamole on CBF. The decrease in PaCO₂ during dipyridamole stress was most likely due to hyperventilation, which was a side effect of adenosine. These results support the hypothesis that circulating adenosine is largely prevented from binding to adenosine receptors of cerebral vessels by the blood-brain barrier. (Stroke. 1999;30:1616-1620.)

Key Words: carbon dioxide ■ cerebral blood flow ■ dipyridamole ■ tomography, emission computed

Dipyridamole produces vasodilation and has been widely used for the measurement of coronary flow reserve.1–3 It inhibits the uptake of adenosine into the erythrocytes4,5 and enhances the vasodilator action of adenosine.4–10 While dipyridamole has been widely used for the measurement of coronary flow reserve in patients with coronary artery disease as well as coronary risk factors,3 it has been reported that coronary atherosclerosis was a important potential risk factor for silent brain infarction.11,12 On the other hand, transient ischemic attack has proved to be a risk factor for myocardial infarction.13 Therefore, dipyridamole stress tests to estimate coronary flow reserve are often performed in patients highly at risk for cerebrovascular diseases, and cerebrovascular accidents during dipyridamole stress tests have been reported.14,15 These accidents were attributed to regional cerebral perfusion changes due to intracranial vascular “steal” phenomenon caused by its vasodilator action. However, the effects of dipyridamole on the cerebral blood flow (CBF) in humans is not pronounced.

Several reports have investigated the effects of intravenous dipyridamole on CBF in animals and largely have been unable to demonstrate any change in CBF after intravenous infusion of dipyridamole in dogs or cats.16–19 However, 1 study did observe increased CBF in rabbits after administration of dipyridamole.16 No increase in global CBF as measured by positron emission tomography (PET) was observed after intravenous adenosine in a limited number of human subjects.20 On the other hand, single-photon emission computed tomography (SPECT) with 99mTc-hexamethylpropyleneamine oxime (99mTc-HMPAO) could demonstrate increased side-to-side asymmetry in occlusive carotid artery disease after intravenous dipyridamole or adenosine administration, claiming the usefulness of intravenous infusion of dipyridamole or adenosine for estimation of cerebral perfusion reserve.21,22 However, the groups did not measure CBF quantitatively, but only estimated relative distribution of brain 99mTc-HMPAO uptake. In addition, there have been no reports as to the CBF response to dipyridamole with relationship to the change of PaCO₂ in humans.

To address some of these conflicting findings, in this study we quantitatively measured CBF after intravenous dipyridamole in 13 healthy subjects with use of 15O-labeled water.
(H<sub>15</sub>O) and PET. The dipyridamole stress CBF values were directly compared with corresponding CBF measurements at rest and during hypercapnia and hypocapnia.

**Subjects and Methods**

**Subjects**
The study was approved by the Ethics Committees of Akita Research Institute of Brain and Blood Vessels. Thirty healthy men (age range 51 to 71 years, mean ± SD 59.4 ± 5.5 years) were recruited and gave written informed consent. The subjects were judged to be healthy on the basis of medical history, physical examination, blood screening analysis, ECG, echocardiography, MRI of the brain, and MR angiography of the brain and the neck. They did not use any medications. The body weight of subjects ranged from 50 to 79 kg. Caffeine intake and theophylline-containing foods or drugs were prohibited for 12 hours before the PET studies.

**PET Procedure**
The Headtome V dual PET (Shimadzu Corp) used for all studies provides 47 sections with center to center distances of 3.125 mm. The intrinsic spatial resolution was 4.0 mm in-plane and 4.3 mm full width at half maximum (FWHM) axially. Reconstruction with a Butterworth filter resulted in a final in-plane resolution of approximately 8 mm FWHM.

The dual PET system allowed simultaneous brain and heart studies to be performed for all studies. After 1 minute of continuous inhalation of C<sub>15</sub>O gas (approximately 5 GBq total supplied to the mouth), a 4-minute static scan was performed and 3 arterial blood samples were taken. The C<sub>15</sub>O PET data in the heart were used to derive the arterial input function for the brain study. After the transmission scan, H<sub>2</sub><sup>15</sup>O PET studies were performed at rest and during hypercapnia, hypocapnia, and dipyridamole stress. The interval between H<sub>2</sub><sup>15</sup>O PET studies was at least 15 minutes. The scanning protocol consisted of a 180-second static scan of the brain and a 360-second dynamic scan of the heart after continuous intravenous infusion of H<sub>2</sub><sup>15</sup>O over 2 minutes. The dose of radioactivity was 1.1 to 1.4 GBq at the time the scanning started. CBF was estimated with the dual PET system, as previously described. Using the arterial input function derived from the left ventricular time-activity curve measured by the PET camera ring positioned over the heart, the CBF images were calculated from the brain PET camera data by the autoradiographic method.

Forced hypercapnia was induced by inhalation of 7% CO<sub>2</sub> gas, starting 1 minute before the beginning of the scan and continuing until the end of scan. Forced hypocapnia was induced by hyperventilation using same schedule as hypercapnia. Dipyridamole (0.56 mg/kg body weight) was intravenously administered over 4 minutes from 8 minutes before the beginning of scan. Three arterial blood samples were taken during each H<sub>2</sub><sup>15</sup>O PET scan to measure PaCO<sub>2</sub>. Blood pressure and heart rate were monitored during each scan. A head fixation system with individual molds for each subject was used to minimize head movement over the period of the PET measurement. The order of the H<sub>2</sub><sup>15</sup>O PET studies was rest, hypercapnia, hypocapnia, and dipyridamole stress in 7 subjects and rest, hypocapnia, hypercapnia, and dipyridamole stress conditions in the other 6 subjects.

**Data Analysis**

Region of interest for inside brain contour was drawn on a slice of CBF image, which was at the basal ganglia level. Mean CBF value in a region of interest was calculated and used for following analyses.

The vascular response to a change in PaCO<sub>2</sub> was calculated as the percent change of CBF per absolute change of PaCO<sub>2</sub> (mm Hg) in response to hypercapnia, hypocapnia, and dipyridamole, as follows:

\[
\frac{100 \times (\text{CBF}_r - \text{CBF}) \times 1}{\text{CBF} \times (\text{PaCO}_2 - \text{PaCO}_2)}
\]

where the subscripts “r” and “a” denote the rest and activation conditions (hypercapnia, hypocapnia, or dipyridamole), respectively.

**Results**

Blood pressure, heart rate, and PaCO<sub>2</sub> during each H<sub>2</sub><sup>15</sup>O PET scan are summarized for each condition in Table 1. Dipyridamole stress PaCO<sub>2</sub> was significantly lower than resting PaCO<sub>2</sub>. No change in blood pressure was observed between the dipyridamole stress and the rest conditions. Blood pressures were measured at the ankle in these studies and are thus approximately 25 mm Hg greater value than pressures measured at the brachium.

The CBF values during rest, hypercapnia, hypocapnia, and dipyridamole stress and the vascular response to PaCO<sub>2</sub> change are given in Table 2. CBF values for dipyridamole stress were significantly lower than those at rest. There was no significant difference in vascular response to PaCO<sub>2</sub> between dipyridamole stress and hypocapnia.

The percent CBF change in response to hypercapnia, hypocapnia, and dipyridamole stress are plotted versus the absolute change of PaCO<sub>2</sub> for all subjects in Figure 1. There was close agreement between the hypocapnia and dipyridamole stress regression lines, and no significant difference in regression slopes or intercepts was observed.

Typical CBF images for the rest, hypercapnia, hypocapnia, and dipyridamole stress conditions are shown in Figure 2. This figure also indicates that the observed CBF changes were global rather than regional.

**Discussion**

Although dipyridamole produces coronary vasodilation, most reports on dipyridamole effects in animals have failed to

**TABLE 1. Blood Pressure, Heart Rate, and PaCO<sub>2</sub> During Each H<sub>2</sub><sup>15</sup>O PET Scan**

<table>
<thead>
<tr>
<th>Condition</th>
<th>BP, mm Hg</th>
<th>HR, beats/min</th>
<th>PaCO&lt;sub&gt;2&lt;/sub&gt;, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rest</td>
<td>146±21/83±12</td>
<td>58±8</td>
<td>40.2±2.4</td>
</tr>
<tr>
<td>Hypercapnia</td>
<td>160±25*/85±11</td>
<td>62±5†</td>
<td>43.1±2.7*</td>
</tr>
<tr>
<td>Hypocapnia</td>
<td>145±27/79±13‡</td>
<td>61±6‡</td>
<td>29.2±3.4*</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>150±33/79±14</td>
<td>73±7*</td>
<td>35.7±2.6*</td>
</tr>
</tbody>
</table>

Values are mean±SD. BP indicates blood pressure (systole/diastole); HR, heart rate.

*P<0.001, †P<0.01, ‡P<0.05 significantly different from rest studies by paired t test.

**TABLE 2. CBF Values During Rest, Hypercapnia, Hypocapnia, and Dipyridamole Stress and the Vascular Response to PaCO<sub>2</sub> Change**

<table>
<thead>
<tr>
<th>Condition</th>
<th>CBF, mL/100 mL/min</th>
<th>Vascular Response to PaCO&lt;sub&gt;2&lt;/sub&gt; Change, %/mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rest</td>
<td>39.8±5.3</td>
<td>...</td>
</tr>
<tr>
<td>Hypercapnia</td>
<td>48.4±10.4*</td>
<td>8.2±5.3</td>
</tr>
<tr>
<td>Hypocapnia</td>
<td>27.0±6.3†</td>
<td>−3.0±1.1†</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>35.6±6.0*†‡</td>
<td>−2.5±1.2‡</td>
</tr>
</tbody>
</table>

Values are mean±SD.

*P<0.001 different from rest studies; †P<0.001, ‡P<0.01 different from hypercapnia studies; and §P<0.001 different from hypocapnia studies, all by paired t test. There was no significant difference in the vascular response between dipyridamole stress and hypocapnia.
show a change in CBF after intravenous infusion of dipyridamole. To our knowledge, this is the first study to quantitatively estimate the change in CBF in response to intravenous dipyridamole in humans. We found CBF values for the dipyridamole stress to be lower than those at rest (Table 2 and Figure 2). Dipyridamole stress also caused a significant reduction in PaCO₂ (Table 1), and the vascular response to PaCO₂ change caused by the dipyridamole infusion closely followed the response due to hypocapnia (Table 2 and Figure 1). Thus, the decrease in CBF during dipyridamole stress can be explained by the decrease in PaCO₂ rather than the direct action of dipyridamole on CBF. The decrease in PaCO₂ during dipyridamole stress is most likely due to the hyperventilation side effect of adenosine. It has been reported that large doses of intravenous adenosine and dipyridamole can induce severe arterial hypotension, severe enough to be out of the range of cerebral autoregulation and hence cause a decrease in CBF. However, no changes in blood pressures were observed between the dipyridamole stress and the rest conditions in the present study.

Human cerebral vessels have A₂ adenosine receptors. The stimulation of these A₂ receptors causes the relaxation of vascular smooth muscle, and this plays a role in the regulation of CBF. However, we did not observe an increase in CBF after intravenous infusion of dipyridamole in this study (Table 2 and Figure 2). The transport of adenosine through the blood-brain barrier has been investigated, and it has been reported that circulating adenosine was unable to cross the blood-brain barrier. Thus, circulating adenosine is unlikely to cause cerebral vasodilation due to its inability to bind to A₂ adenosine receptors of cerebral vessels. Although it is unknown whether intravenous dipyridamole is transferred across the blood-brain barrier to increase the concentration of interstitial adenosine in humans, it has been reported that dipyridamole could not be transferred across the blood brain barrier in rat and mouse, which further supports our findings.

The cerebrovascular accidents during dipyridamole stress tests have been reported and have been attributed to intracranial vascular steal phenomenon. However, because intravenous dipyridamole does not increase the CBF (Table 2 and Figure 2), the intracranial vascular steal phenomenon cannot occur. On the contrary, CBF was reduced during dipyridamole stress due to a decrease in PaCO₂ caused by adenosine-induced hyperventilation. Recently, posthyperventilatory steal response in chronic cerebral hemodynamic stress has been reported. If severe hypocapnia is caused by intravenous dipyridamole, a regional cerebral perfusion disturbance might be caused. In addition, it has been reported that coronary atherosclerosis is an important potential risk factor for cerebrovascular diseases. In dipyridamole stress testing to estimate coronary flow reserve, such complications should thus be considered.

SPECT studies with ⁹⁹mTc-HMPAO have shown an increased side-to-side asymmetry in occlusive carotid artery disease following intravenous dipyridamole or adenosine administration, and it was concluded that dipyridamole or adenosine was a cerebral vasodilator and was useful for estimating cerebral perfusion reserve. However, in the present study, intravenous dipyridamole decreased global CBF due to a decrease in PaCO₂ attributed to the hyperventilation caused by adenosine. ⁹⁹mTc-HMPAO suffers from back-diffusion from the brain to the blood, and its first-pass
The inhalation of CO₂ gas has been widely used for estimation of cerebral perfusion reserve. In the present study, hypercapnia increased global CBF by 8±5% (mean±SD) per unit PaCO₂ change (mm Hg) in healthy subjects (Table 2). Large interindividually variation of vascular response to hypercapnia was observed even in healthy subjects. On the other hand, the hypocapnia induced by hyperventilation decreased global CBF by 3±1% per unit PaCO₂ change, and the degree of this response was smaller than that for the hypercapnia (Table 2). These results are in good agreement with previous reports.

In conclusion, dipyridamole decreased CBF due to a decrease in PaCO₂ caused by adenosine-induced hyperventilation and did not directly change CBF, despite being a potent coronary vasodilator. Because severe hypocapnia might cause a regional cerebral perfusion disturbance, such side effects during dipyridamole stress tests to evaluate coronary flow reserve should be considered.

Acknowledgments

This work was supported by grants from the Ministry of Health and Welfare (cardiovascular disease: SC-5, 1996–1998) and Akita Research Institute of Brain and Blood Vessels. The assistance of the members of the Akita Research Institute of Brain and Blood Vessels in performing the PET experiments is also greatly acknowledged.

References


Effect of Intravenous Dipyridamole on Cerebral Blood Flow in Humans: A PET Study
Hiroshi Ito, Toshibumi Kinoshita, Yoshikazu Tamura, Ikuo Yokoyama and Hidehiro Iida

Stroke. 1999;30:1616-1620
doi: 10.1161/01.STR.30.8.1616
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/30/8/1616

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/